ReviewBlood2015
Aberrant B-cell homeostasis in chronic GVHD.
Review in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed.
- Deciphering bone marrow engraftment after allogeneic stem cell transplantation in humans using single-cell analyses.The Journal of clinical investigation · 2024Trial
- Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation.Blood advances · 2024Trial
- Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study.Stem cells translational medicine · 2020Trial
- Measuring the cellular memory B cell response after vaccination in patients after allogeneic stem cell transplantation.Annals of hematology · 2020Trial
- Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Trial
- B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.Bone marrow transplantation · 2017Trial
- Early Marrow Microenvironment Immune Patterns After Hematopoietic Stem Cell Transplant in Pediatric Acute Lymphoblastic Leukemia Are Associated with Later Development of Chronic GvHD and Relapse.International journal of molecular sciences · 2026Article
- Delayed B-cell reconstitution in the bone marrow precedes the development of chronic graft-versus-host disease following pediatric hematopoietic stem cell transplantation.Frontiers in immunology · 2026Article
- New age GVHD prophylaxis regimens: what works for what donor and why.Hematology. American Society of Hematology. Education Program · 2025Review
- Association of donor and recipient single-nucleotide polymorphisms of interleukin-1 gene with outcomes after allogeneic hematopoietic stem cell transplantation in childhood.Journal of cancer research and clinical oncology · 2025Article
- Expansion of peripheral helper T cells in the peripheral blood of patients with chronic graft-versus-host disease.Annals of hematology · 2025Article
- Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part II. Organ Dysfunction and Immune Reconstitution Considerations for Children with Chronic Graft-versus-Host Disease after Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2025Article
- What's atypical about human B cells after allogeneic stem cell transplantation?Journal of leukocyte biology · 2025Review
- Interleukin 35-producing B cells prolong the survival of GVHD mice by secreting exosomes with membrane-bound IL-35 and upregulating PD-1/LAG-3 checkpoint proteins.Theranostics · 2025Article
- Review
- How does ocular graft-versus-host disease fit under the dry eye umbrella? A review.Clinical & experimental ophthalmology · 2024Review
- Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood advances · 2023Article
- Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death.The Journal of clinical investigation · 2023Article
- Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD.JCI insight · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recent studies have compelled further interest in the potential pathological role of B cells in chronic graft-versus-host disease (cGVHD). In patients with cGVHD, B cells are activated and primed for survival via B-cell activating factor and B-cell receptor-associated pathways. Understanding the signaling pathways that drive immune pathology in cGVHD will facilitate the development of new strategies to selectively target aberrantly activated B cells and restore normal B-cell homeostasis after allogeneic stem cell transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.